[{"id":"9019c921-3c37-404e-9dcf-6b18ca280688","acronym":"EPI VITRAKVI","url":"https://clinicaltrials.gov/study/NCT05236257","created_at":"2022-02-11T12:52:54.392Z","updated_at":"2025-02-25T17:12:08.743Z","phase":"","brief_title":"A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database","source_id_and_acronym":"NCT05236257 - EPI VITRAKVI","lead_sponsor":"Bayer","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 09/13/2022","primary_completion_date":" 09/13/2022","study_txt":" Completion: 09/13/2022","study_completion_date":" 09/13/2022","last_update_posted":"2024-12-10"},{"id":"9eaee900-c56a-440b-bf3e-d9e5c14d97d5","acronym":"ADVL1823","url":"https://clinicaltrials.gov/study/NCT03834961","created_at":"2021-01-18T18:56:06.238Z","updated_at":"2024-07-02T16:35:13.156Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia","source_id_and_acronym":"NCT03834961 - ADVL1823","lead_sponsor":"Children's Oncology Group","biomarkers":" NTRK1 • NTRK3 • NTRK2 • ETV6","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2 • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/25/2019","start_date":" 10/25/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-22"},{"id":"cbadcf07-a7e7-4ec4-b497-346814eb3bc4","acronym":"LIBRETTO-121","url":"https://clinicaltrials.gov/study/NCT03899792","created_at":"2021-01-18T19:12:12.872Z","updated_at":"2024-07-02T16:35:15.915Z","phase":"Phase 1/2","brief_title":"A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors","source_id_and_acronym":"NCT03899792 - LIBRETTO-121","lead_sponsor":"Loxo Oncology, Inc.","biomarkers":" RET","pipe":"","alterations":" ","tags":["RET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Retevmo (selpercatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/13/2019","start_date":" 06/13/2019","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2024-03-07"},{"id":"a010e6ed-344f-428e-a888-60e487dd1787","acronym":"SALA-002-EW16","url":"https://clinicaltrials.gov/study/NCT03600649","created_at":"2021-04-14T16:53:42.104Z","updated_at":"2024-07-02T16:35:28.552Z","phase":"Phase 1","brief_title":"Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas","source_id_and_acronym":"NCT03600649 - SALA-002-EW16","lead_sponsor":"Salarius Pharmaceuticals, LLC","biomarkers":" EWSR1","pipe":"","alterations":" ","tags":["EWSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • topotecan • seclidemstat (SP2577)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/04/2018","start_date":" 06/04/2018","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-11-21"},{"id":"640b8ea4-dbbe-4ef7-aaf3-6fff167a55c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03009201","created_at":"2021-01-18T14:48:19.930Z","updated_at":"2025-02-25T15:53:37.006Z","phase":"Phase 1b","brief_title":"Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03009201","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" RB1","pipe":"","alterations":" ","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Kisqali (ribociclib)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/10/2017","start_date":" 03/10/2017","primary_txt":" Primary completion: 10/08/2019","primary_completion_date":" 10/08/2019","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2023-08-16"},{"id":"1143e6ad-4fb3-4eac-a9d3-83858e654c43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01614795","created_at":"2021-01-18T06:55:05.325Z","updated_at":"2024-07-02T16:37:04.745Z","phase":"Phase 2","brief_title":"Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma","source_id_and_acronym":"NCT01614795","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR • IR","pipe":"","alterations":" ","tags":["mTOR • IR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temsirolimus • cixutumumab (IMC A12)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/18/2012","start_date":" 06/18/2012","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2018-12-11"}]